Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling

MLA

Chezi Ganzel, et al. “Measurable Residual Disease by Flow Cytometry in Acute Myeloid Leukemia Is Prognostic, Independent of Genomic Profiling.” Leukemia Research, vol. 123, May 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8825d804e6d4ff115c5966524a27664b&authtype=sso&custid=ns315887.

APA

Chezi Ganzel, Zhuoxin Sun, Timour Baslan, Yanming Zhang, Mithat Gönen, Omar I. Abdel-Wahab, Janis Racevskis, Francine Garrett-Bakelman, Scott W. Lowe, Hugo F. Fernandez, Rhett Ketterling, Selina M. Luger, Mark Litzow, Hillard M. Lazarus, Jacob M. Rowe, Martin S. Tallman, Ross L. Levine, & Elisabeth Paietta. (2022). Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. Leukemia Research, 123.

Chicago

Chezi Ganzel, Zhuoxin Sun, Timour Baslan, Yanming Zhang, Mithat Gönen, Omar I. Abdel-Wahab, Janis Racevskis, et al. 2022. “Measurable Residual Disease by Flow Cytometry in Acute Myeloid Leukemia Is Prognostic, Independent of Genomic Profiling.” Leukemia Research 123 (May). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8825d804e6d4ff115c5966524a27664b&authtype=sso&custid=ns315887.